IceCure Medical's Significant Advancement
IceCure has reached an important milestone with its ProSense cryoablation system, becoming the first medical device to receive FDA marketing authorization for the localized treatment of breast cancer. This marks a revolutionary achievement in the field of minimally invasive cancer treatment.
Participation in the Maxim Growth Summit
The management team at IceCure Medical, including CEO Eyal Shamir, will take part in the upcoming Maxim Growth Summit. This event is designed for meaningful interactions with institutional investors, allowing a closer look at IceCure's latest developments, regulatory achievements, and commercial progress both in the U.S. and internationally.
Innovative Cryoablation Technology
The ProSense system is a groundbreaking approach to treating early-stage breast cancer in patients aged 70 and older, particularly those who may not be suitable for surgery. This innovative technology serves as a new option, potentially transforming healthcare standards for these patients.
Investor Engagement Opportunities
Investors interested in setting up meetings with IceCure Medical's management during the summit can do so through their Maxim sales representatives or by contacting Michael Polyviou directly via email.
About IceCure Medical
IceCure Medical, traded under NASDAQ: ICCM, focuses on developing and marketing advanced cryoablation systems. Their technology uses liquid nitrogen to freeze and destroy tumors effectively. With a primary emphasis on cancers affecting the breast, kidney, bone, and lung, IceCure's system represents a significant shift in treatment methodologies, allowing for procedures that are less invasive and can be performed more swiftly. Their ProSense system is already being marketed globally, affirming its wide-ranging acceptance and potential.
Frequently Asked Questions
What significant milestone did IceCure Medical recently achieve?
IceCure Medical's ProSense cryoablation system received FDA marketing authorization for local breast cancer treatment.
Who from IceCure Medical will attend the Maxim Growth Summit?
CEO Eyal Shamir and members of the management team will participate in the summit.
What is the focus of IceCure Medical's cryoablation technology?
The technology focuses on treating various types of cancer, particularly in older patients who are not suitable for surgery.
How can investors engage with IceCure during the summit?
Investors can meet IceCure's management by reaching out to their Maxim sales representatives or contacting Michael Polyviou.
Where is IceCure Medical's ProSense system marketed?
The ProSense system is marketed globally, including in the U.S., Europe, and Asia, showcasing its international reach.
